Preeclampsia Possible
Conditions
Keywords
Asprin, Pregnancy
Brief summary
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Interventions
DRUGAspirin
81mg twice a day (162mg total)
Sponsors
NYU Langone Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Pregnant people prior to 17 weeks * Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates * Age 18-50 years * Singleton viable gestation * Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.
Exclusion criteria
* Undergoing glucose challenge test (GCT) at time of blood draw * Allergy or intolerance to aspirin * Antithrombotic or antiplatelet therapy * Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (platelet count \<100,000), or thrombocytosis (platelet count \>600,000) * Known hemorrhagic diathesis * Planned delivery outside of NYU
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA) | Baseline, 4 weeks after initiation of aspirin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in serum thromboxane | Baseline, 4 weeks after initiation of aspirin | — |
| Change in complete blood count | Baseline, 4 weeks after initiation of aspirin | — |
| Change in Mean Platelet Volume (MPV) | Baseline, 4 weeks after initiation of aspirin | — |
| Change in Platelet Distribution Width (PDW) | Baseline, 4 weeks after initiation of aspirin | — |
| Change in Plateletcrit (PCT) | Baseline, 4 weeks after initiation of aspirin | — |
| Change in Life's Essential 8 questionnaire | Baseline, 4 weeks after initiation of aspirin | Life's Essential 8 (LE8) is a cardiovascular health scoring system from the American Heart Association that rates health from 0 to 100 based on diet, activity, smoking, sleep, BMI, cholesterol, blood sugar, and blood pressure. Scores indicate high cardiovascular health, 50-79 is moderate, and below 50 is low. A score of 100 is ideal, while 0 represents the lowest health condition, such as severe, uncontrolled risk factors. |
Countries
United States
Contacts
CONTACTChristina A. Penfield, MD, MPH
CONTACTLucia Muzzarelli
PRINCIPAL_INVESTIGATORChristina A. Penfield, MD, MPH
NYU Langone Health
Outcome results
None listed